Welcome to the Slashdot Beta site -- learn more here. Use the link in the footer or click here to return to the Classic version of Slashdot.

Thank you!

Before you choose to head back to the Classic look of the site, we'd appreciate it if you share your thoughts on the Beta; your feedback is what drives our ongoing development.

Beta is different and we value you taking the time to try it out. Please take a look at the changes we've made in Beta and  learn more about it. Thanks for reading, and for making the site better!

What Bilski Meant for Biotech Patents

eldavojohn (898314) writes | more than 3 years ago

Biotech 0

eldavojohn writes "Patents aren't just a software thing and while Bilski's Dismissal didn't shake the ground for software, it certainly is making waves in the biotech community. You may recall Prometheus v. Mayo in which doctors fought a biotech startup's methodology patents. Well, medical method patents (like Prometheus and another) are now being reconsidered on orders by the Supreme Court of certiorari (judicial review). Stocks of biotech startups jumped as this news broke but the question still remains how the lower Federal Circuit court will rule when it reconsiders these cases of medical testing. It's clear that the Supreme Court has 'ruled that judges should be more flexible in determining if methods, rather than objects, are eligible for patents, citing emerging technologies such as medical testing.' So Bilski may result in dire news for medical methods and testing patents."
Link to Original Source

0 comment

Check for New Comments
Slashdot Account

Need an Account?

Forgot your password?

Don't worry, we never post anything without your permission.

Submission Text Formatting Tips

We support a small subset of HTML, namely these tags:

  • b
  • i
  • p
  • br
  • a
  • ol
  • ul
  • li
  • dl
  • dt
  • dd
  • em
  • strong
  • tt
  • blockquote
  • div
  • quote
  • ecode

"ecode" can be used for code snippets, for example:

<ecode>    while(1) { do_something(); } </ecode>
Sign up for Slashdot Newsletters
Create a Slashdot Account